Literature DB >> 2503922

Immunogenicity of Brucella abortus salt-extractable proteins.

L B Tabatabai1, B L Deyoe, J M Patterson.   

Abstract

The immunogenic properties of salt-extractable proteins and chromatographic fractions thereof from Brucella abortus were evaluated in lemmings (Dicrostonyx rubricatus). The efficacy of the Brucella proteins as immunogens was determined after challenge with virulent B. abortus strain 2308 and was based on protection against clinical signs and gross lesions of brucellosis, as well as on numbers of viable Brucella in the spleen. Vaccination of lemmings with as little as 0.1 microgram of salt-extractable proteins (CSP) suppressed splenic infection, resulting in reduced numbers of viable organisms per spleen of 5-6 logs compared to non-vaccinated controls. Protein fractions separated by column chromatography were generally effective in reducing splenic infection, and contained proteins with molecular weights of 30,000, 20,000 and 12,000. Vaccines containing chemically modified dodecanoyl-CSP offered no additional advantage over unmodified CSP vaccines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503922     DOI: 10.1016/0378-1135(89)90006-0

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  11 in total

1.  TLR2 and TLR4 signaling pathways are required for recombinant Brucella abortus BCSP31-induced cytokine production, functional upregulation of mouse macrophages, and the Th1 immune response in vivo and in vitro.

Authors:  Jia-Yun Li; Yuan Liu; Xiao-Xue Gao; Xiang Gao; Hong Cai
Journal:  Cell Mol Immunol       Date:  2014-04-28       Impact factor: 11.530

2.  Protective efficacy of a Brucella vaccine using a Salmonella-based delivery system expressing Brucella Omp3b, BCSP31, and SOD proteins against brucellosis in Korean black goats.

Authors:  Won-Kyong Kim; Ja-Young Moon; Jeong-Sang Cho; Jin Hur
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

3.  Cloning, expression, and occurrence of the Brucella Cu-Zn superoxide dismutase.

Authors:  B J Bricker; L B Tabatabai; B A Judge; B L Deyoe; J E Mayfield
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

4.  Alteration of protective and serologic responses in BALB/c mice vaccinated with chemically modified versus nonmodified proteins of Brucella abortus 19.

Authors:  G W Pugh; L B Tabatabai
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

5.  Variation of Brucella abortus 2308 infection in BALB/c mice induced by prior vaccination with salt-extractable periplasmic proteins from Brucella abortus 19.

Authors:  G W Pugh; L B Tabatabai
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

6.  Cytokine production in the murine response to brucella infection or immunization with antigenic extracts.

Authors:  Y Zhan; A Kelso; C Cheers
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

7.  Cell response to a salt-extractable and sonicated Brucella melitensis 16M antigen in human brucellosis.

Authors:  M C Moreno-Lafont; A López-Merino; R López-Santiago
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

8.  Cytokine response of T-cell subsets from Brucella abortus-infected mice to soluble Brucella proteins.

Authors:  Y Zhan; J Yang; C Cheers
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

9.  Protective efficacy by various doses of a new brucellosis vaccine candidate based on Salmonella strains expressing Brucella abortus BSCP31, Omp3b and superoxide dismutase against brucellosis in murine model.

Authors:  Won Kyong Kim; Ja Young Moon; Jeong Sang Cho; Jin Hur
Journal:  Pathog Dis       Date:  2017-09-29       Impact factor: 3.166

10.  Comparison between Immunization Routes of Live Attenuated Salmonella Typhimurium Strains Expressing BCSP31, Omp3b, and SOD of Brucella abortus in Murine Model.

Authors:  Won K Kim; Ja Y Moon; Suk Kim; Jin Hur
Journal:  Front Microbiol       Date:  2016-04-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.